Profound Medical to release Q2 2026 results on August 6

Profound Medical Corp. will announce its second quarter 2026 financial results after market close on Thursday, August 6, 2026. The company, a commercial-stage medical device firm specializing in interventional MRI (iMRI) procedures, will provide details on its financial performance and business developments during the period. Management will host a conference call at 4:30 p.m. ET to review the results.

Conference Call Details

Investors and analysts can participate in the live call to gain insights into Profound Medical's quarterly performance. The discussion will cover financial metrics and operational updates, including developments related to its flagship TULSA-PRO platform and Sonalleve therapy.

Event	Details
Date	Thursday, August 6, 2026
Time	4:30 p.m. ET
Registration	Live Call Registration Link

The call will be broadcast live and archived on the company's website in the Investors section. Profound Medical's technologies, including TULSA-PRO for prostate ablation and Sonalleve for non-surgical treatments, are approved across major global markets such as the United States, Europe, and Canada.

Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) will highlight its MRI-guided, AI-powered, robotically-driven TULSA Procedure at the Society of Robotic Surgery (SRS) Annual Meeting in Fort Lauderdale, FL, from July 23-26, 2026. The company's technology will be featured in multiple presentations by leading physicians, focusing on clinical outcomes, safety data, and the integration of artificial intelligence in prostate cancer treatment. Profound has also been selected as one of eight companies spotlighted during the Society of Incisionless Surgery (SIS) plenary session.

Clinical Presentations and Outcomes

Several presentations will examine the efficacy and safety of the TULSA Procedure across different clinical scenarios. Key sessions include:

Presentation Title	Presenter	Date & Time (EDT)
Real-world Outcomes after MRI-guided Transurethral Ultrasound Ablation	Xiaosong Meng, MD, PhD, UT Southwestern Medical Center	July 24, 2026; 9:55-10:00 a.m.
CAPTAIN Trial: TULSA vs. Radical Prostatectomy Safety Outcomes	Xiaosong Meng, MD, PhD, UT Southwestern Medical Center	July 24, 2026; 10:00-10:04 a.m.
Single-Center Efficacy and Safety Outcomes	Xiaosong Meng, MD, PhD, UT Southwestern Medical Center	July 24, 2026; 10:30-10:34 a.m.
Intermediate Term Outcomes for Extreme Apical Prostate Cancer	Victoria Y. Bird, MD, National Medical Association	July 24, 2026; 10:46-10:50 a.m.
Salvage TULSA for Locally Recurrent Prostate Cancer	Victoria Y. Bird, MD, National Medical Association	July 24, 2026; 10:50-10:55 a.m.

Dr. Xiaosong Meng noted that UT Southwestern reached the 100th procedure milestone in 2022, prior to the CPT Category 1 codes becoming effective in January 2025.

Society of Incisionless Surgery Spotlight

The SIS, which held its inaugural board meeting in March 2026, will host a plenary session focusing on the future of surgery, including energy-based treatment, image guidance, and robotics. Profound Medical was selected as one of eight companies to present during this session.

Session Title	Presenter	Date & Time (EDT)
Incisionless Precision: Imaging, AI, and Robotic Autonomy	Y. Mark Hong, MD, Integrative Urology	July 26, 2026; 10:35-10:42 a.m.

Dr. Y. Mark Hong emphasized that the TULSA-PRO platform combines real-time MRI guidance, artificial intelligence, and supervised robotic autonomy to enable personalized treatment based on patient anatomy.

Investor Session Participation

Prior to the clinical program, Profound's management team will participate in an investor session on July 22, 2026, moderated by Rick Wise of Stifel Financial and Larry Biegelsen of Wells Fargo.

Session Title	Presenter	Date & Time (EDT)
Innovative Robotic Technologies	Arun Menawat, PhD, Profound Medical	July 22, 2026; 10:45-11:15 a.m.
Profound Medical: TULSA-PRO	Tom Tamberrino, Profound Medical	July 22, 2026; 1:05-1:10 p.m.

Dr. Arun Menawat stated that SRS2026 provides a unique opportunity to connect with surgeons, researchers, and investors to accelerate robotic-assisted surgery adoption.